Grünenthal Group

Janneke van der Kamp joins Grünenthal as new Chief Commercial Officer

Del
Janneke van der Kamp joins Grünenthal as new Chief Commercial Officer / Copyright Grünenthal Group
Janneke van der Kamp joins Grünenthal as new Chief Commercial Officer / Copyright Grünenthal Group

AACHEN, Germany, 22 November 2022 –Grünenthal today announced that Janneke van der Kamp will join Grünenthal as the new Chief Commercial Officer (CCO), effective 1 March 2023. Janneke van der Kamp joins Grünenthal from Novartis, where she most recently served as Head of Pharma Region Europe. The Dutch native brings broad experience in the pharmaceutical industry from several roles including General Manager, Global Neurosciences Franchise Head and Global Head of Product and Portfolio Strategy for the entire Novartis Pharma portfolio. She worked closely with Research & Development and the Licensing & Acquisitions teams to strengthen the company’s pipeline. Janneke van der Kamp has vast expertise in launching and growing key brands across several disease areas. She is a studied chemist and holds an MBA from INSEAD.

As CCO of Grünenthal, Janneke van der Kamp will be responsible for the entire Global Commercial Organisation and serve as a member of the Corporate Executive Board. Her focus will be to continue to grow the company’s key brands, prepare for the launch of Grünenthal’s pipeline assets and maximise the portfolio of established medicines.

“Grünenthal is a company with an excellent commercial performance and a compelling vision of a World Free of Pain”, says Janneke van der Kamp. “I am looking forward to meeting the teams around the world and together drive the growth of Grünenthal’s portfolio and prepare to bring new medicines to patients.”

Janneke van der Kamp succeeds Grünenthal’s current CCO, Mark Fladrich, who will retire from Grünenthal effective 28 February 2023. Over the past five years, Mark Fladrich has transformed Grünenthal’s commercial organisation. Key achievements included attracting and developing talents and the creation of a strong, patient and customer-oriented culture to support Grünenthal's vision of a World Free of Pain. Under his leadership, the European and Latin American businesses have been transformed, and Grünenthal has successfully entered the US market. The Grünenthal product portfolio has consistently grown which has contributed to the company’s strong profit growth over the last five years.

“With Janneke, we gain an exceptional leader with an excellent track record of developing high-performing, diverse teams and launching industry-leading brands. We are excited to welcome her to the team,” says Gabriel Baertschi, Chief Executive Officer Grünenthal.

“I want to thank Mark for everything he has done for Grünenthal, our portfolio and our people. His leadership, counsel and character will be missed. I wish him and his family all the best for the future.”

Kontakter

Fabia Kehren
Head of External Communication
Grünenthal GmbH
52099 Aachen
Phone: +49 241 569-3269
E-mail: Fabia.Kehren@grunenthal.com

Florian Dieckmann
Head Global Communication
Grünenthal GmbH
52099 Aachen
E-mail: Florian.Dieckmann@grunenthal.com

Billeder

Janneke van der Kamp joins Grünenthal as new Chief Commercial Officer / Copyright Grünenthal Group
Janneke van der Kamp joins Grünenthal as new Chief Commercial Officer / Copyright Grünenthal Group
Download

Information om Grünenthal Group

Grünenthal Group
Grünenthal Group

Aachen, Germany

Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain.

Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America and the US. Our products are available in more than 100 countries. In 2021, Grünenthal employed around 4,500 people and achieved sales of € 1.5 bn.

More information: www.grunenthal.com

Click here for our Grünenthal Report 2021/2022

Follow us on:

LinkedIn: Grunenthal Group

Instagram: grunenthal

Følg pressemeddelelser fra Grünenthal Group

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Grünenthal Group

Grünenthal starts Phase III trials for resiniferatoxin in osteoarthritis-related pain18.8.2022 13:24:23 CEST | Pressemeddelelse

Global Phase III programme to enable marketing authorisation in the EU, the US and Japan for an innovativenon-opioid investigational medicine. The programme will be conducted across approx. 200 study sites and include more than 1800 patients suffering from pain associated with osteoarthritis. Globally, more than 300 million patients suffer from osteoarthritis[1]. The global osteoarthritis market is expected to grow to approximately $11.0 billion in 2025[2]. Aachen, Germany – 18 August 2022 –Grünenthal announced today that the company has enrolled the first patient in its global clinical Phase III programme for resiniferatoxin (RTX). RTX is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist, with a well-validated mechanism of action. The discovery of TRPV1 was awarded the Nobel Prize of Physiology or Medicine in 2021. If approved, resiniferatoxin may provide patients with long-lasting pain relief with a favourable safety profile. Grünenthal’s Phase III programme wi

Grünenthal to license osteoarthritis pain treatment to Shionogi in Japan in deal of up to > $ 500 million4.8.2022 09:00:00 CEST | Pressemeddelelse

Grünenthal to license osteoarthritis pain treatment to Shionogi in Japan in deal of up to > $ 500 million Aachen, Germany – 4 August 2022 – Grünenthal and Shionogi announced today that they have entered into a licensing agreement for Grünenthal’s investigational medicine Resiniferatoxin (“RTX”). Shionogi obtained the exclusive rights to commercialise Grünenthal’s asset in Japan for pain associated with osteoarthritis of the knee. RTX is currently in Phase III of clinical development for the treatment of patients with moderate to severe pain associated with knee osteoarthritis. Osteoarthritis, a progressive and often painful joint disease, is an indication with high unmet medical need. If approved, RTX could become a well-tolerated, non-opioid therapy option for patients, providing long-lasting pain relief and functional improvement of the affected knee joints. Under the terms of the agreement, Shionogi will obtain the exclusive commercialisation rights for RTX in Japan for a total cons

Grünenthal acquires testosterone treatment NebidoTM from Bayer14.7.2022 09:05:26 CEST | Press release

Grünenthal acquires NebidoTM from Bayer AG for up to € 500 million. The product is expected to add about € 100 million to Grünenthal’s EBITDA in 2023. NebidoTM is the gold standard for the treatment ofmale hypogonadism associated with testosterone deficiency. It is available to patients in over 80 markets worldwide. Grünenthal has invested over € 2 billion in successful M&A transactions over the last years, resulting in a significantly strengthened profitability. Aachen, Germany, 14 July 2022 –Grünenthal, a global science-based, privately-owned pharmaceutical company, today announced an agreement with Bayer AG to acquire NebidoTM, the well-known brand for the treatment of male hypogonadism and its associated brands for up to € 500 million. NebidoTM is the only long-acting injectable treatment for testosterone deficiency. The product is approved and successfully commercialized in over 80 countries. Patent protection exists until March 2024 in the EU and until May 2027 in the US. The bra

Grünenthal, Uniklinik RWTH Aachen and RTWH Aachen University collaborate to advance pain research7.7.2022 09:05:00 CEST | Press release

Aachen, Germany – 7 July 2022 – Grünenthal, Uniklinik RWTH Aachen and RWTH Aachen University announced a collaboration to advance the development of next-generation pain medicines. The collaboration involves the institutes of Dr Angelika Lampert, Professor of Physiology at the Uniklinik RWTH Aachen and Dr Marc Spehr, Lichtenberg-Professor for Chemosensation at the RWTH Aachen University. The partners strive to develop a range of translational research tools and humanised preclinical models to enhance target validation. Under the terms of the agreement, Grünenthal will support the institutes led by Professor Lampert and Professor Spehr with approximately € 1 million of funding. Part of the funding allows for establishing two new post-doc positions. The exploratory efforts at the Uniklinik RWTH Aachen and RWTH Aachen University will, if successful, enable their subsequent integration into drug development activities at Grünenthal. Chronic pain is a considerable burden that impacts up to

Grünenthal and NovaQuest enter agreement to advance the resiniferatoxin global Phase III program in osteoarthritis29.3.2022 12:05:00 CEST | Press release

Grünenthal and NovaQuest announced today that they have entered into an agreement to advance the global clinical Phase III programme of Grünenthal's asset resiniferatoxin (RTX). The investigational medicine is being developed with the aim of providing patients suffering from pain associated with osteoarthritis with a well-tolerated, non-opioid therapy option that is intended to provide long-lasting pain relief and functional improvement of the affected joints. RTX is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist with a well-validated mechanism of action. The Phase III trials will investigate the efficacy, safety and tolerability of RTX in patients with pain associated with osteoarthritis of the knee. The trials will start in 2022 and are designed to meet the requirements for marketing approval in the EU, the US, and Japan. "Globally, more than 300 million patients suffer from osteoarthritis[1]. For many of them, the available treatment options are not suffici